James P Allison

List of Publications by Year
in descending order

275 papers	83,684 citations	558 126 h-index	460 272 g-index
283 all docs	283 docs citations	283 times ranked	65119 citing authors

#	Article	IF	Citations
1	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science Translational Medicine, 2022, 14, eabm6420.	12.4	29
2	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell, 2022, 40, 509-523.e6.	16.8	115
3	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitorâ€“Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discovery, 2021, 11, 614-625.	9.4	145
4	Frontiers in cancer immunotherapyâ€"a symposium report. Annals of the New York Academy of Sciences, 2021, 1489, 30-47.	3.8	39
5	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
6	First-in-Human Phase I Study of ABBV-085, an Antibodyâ€“Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3556-3566.	7.0	21
7	The Next Decade of Immune Checkpoint Therapy. Cancer Discovery, 2021, 11, 838-857.	9.4	363
8	LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. Journal of Experimental Medicine, 2021, 218, .	8.5	53
9	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2021, 27, 4557-4565.	7.0	61
10	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
11	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nature Communications, 2021, 12, 5045.	12.8	42
12	Checkpoint Blockade + Chemotherapy: the Right Combination for AML?. Blood Cancer Discovery, 2021, 2, 551-554.	5.0	2
13	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nature Communications, 2021, 12, 6071.	12.8	44
14	Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naÃ¯ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. , 2021, 9, e002919.		30
15	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science, 2021, 374, 1632-1640.	12.6	369
16	Dissecting the mechanisms of immune checkpoint therapy. Nature Reviews Immunology, 2020, 20, 75-76.	22.7	275
17	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nature Medicine, 2020, 26, 39-46.	30.7	236
18	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine, 2020, 26, 1845-1851.	30.7	193

#	ARTICLE	IF	CITATIONS
19	<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Science Translational Medicine, 2020, 12, .	12.4	82
20	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine, 2020, 12, .	12.4	108
21	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications, 2020, 11, 1839.	12.8	15
22	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	12.8	140
23	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight, 2020, 5, .	5.0	130
24	Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. Blood, 2020, 136, 29-31.	1.4	0
25	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. Blood, 2020, 136, 43-45.	1.4	10
26	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clinical Cancer Research, 2019, 25, 1233-1238.	7.0	260
27	Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunology Research, 2019, 7, 1390-1395.	3.4	54
28	Characterization and Comparison of GITR Expression in Solid Tumors. Clinical Cancer Research, 2019, 25, 6501-6510.	7.0	37
29	Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunology Research, 2019, 7, 1803-1812.	3.4	31
30	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22246-22251.	7.1	142
31	Combination antiâ€“CTLA-4 plus antiâ€“PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22699-22709.	7.1	226
32	Antiâ€“CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancersâ€"Response. Clinical Cancer Research, 2019, 25, 3469-3470.	7.0	151
33	TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10453-10462.	7.1	53
34	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	3.8	459
35	Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity, 2019, 50, 1084-1098.e10.	14.3	75
36	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiationâ€“Related Abscopal Responses. Cancer Immunology Research, 2019, 7, 1903-1909.	3.4	86

#	Article	IF	Citations
37	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383.	9.4	380
38	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. JCI Insight, 2019, 4, .	5.0	8
39	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. Blood, 2019, 134, 830-830.	1.4	38
40	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 2018, 6, 189-200.	3.4	102
41	Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clinical Cancer Research, 2018, 24, 1011-1018.	7.0	31
42	Gut microbiome modulates response to antiâ€“PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	12.6	3,126
43	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine, 2018, 24, 1804-1808.	30.7	521
44	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 2018, 8, 1069-1086.	9.4	2,128
45	Modulation of EZH2 expression in T cells improves efficacy of antiâ€“CTLA-4 therapy. Journal of Clinical Investigation, 2018, 128, 3813-3818.	8.2	169
46	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 905-905.	1.4	21
47	Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood, 2018, 132, 906-906.	1.4	13
48	A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation. Blood, 2018, 132, 296-296.	1.4	27
49	Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Blood, 2018, 132, 4585-4585.	1.4	1
50	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunology Research, 2017, 5, 100-105.	3.4	46
51	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	12.4	689
52	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 2017, 8, 14340.	12.8	110
53	Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nature Communications, 2017, 8, 15095.	12.8	432
54	Fc Gamma R. , 2017, , 209-228.		0

#	Article	IF	Citations
55	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 2017, 23, 551-555.	30.7	467
56	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	3.8	120
57	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications, 2017, 8, 451.	12.8	107
58	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	9.4	160
59	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 2017, 170, 1120-1133.e17.	28.9	960
60	Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. Journal of Immunology, 2017, 199, 974-981.	0.8	5
61	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Research, 2017, 77, 839-850.	0.9	195
62	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohnâ€™s disease: a case report. Journal of Hematology and Oncology, 2016, 9, 81.	17.0	62
63	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunology Research, 2016, 4, 279-288.	3.4	29
64	ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40â€“Mediated Tumor Rejection. Cancer Research, 2016, 76, 3684-3689.	0.9	47
65	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11919-11924.	7.1	197
66	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clinical Cancer Research, 2016, 22, 5729-5737.	7.0	175
67	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunology Research, 2016, 4, 835-844.	3.4	138
68	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications, 2016, 7, 12632.	12.8	648
69	Loss of IFN-Î³ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell, 2016, 167, 397-404.e9.	28.9	1,009
70	Interdependent IL-7 and IFN-Î³ signalling in T-cell controls tumour eradication by combined Î±-CTLA-4+Î±-PD-1 therapy. Nature Communications, 2016, 7, 12335.	12.8	93
71	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	9.4	785
72	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	4.6	55

#	Article	IF	Citations
73	Friends Not Foes: CTLA-4 Blockade and mTOR Inhibition Cooperate during CD8+ T Cell Priming To Promote Memory Formation and Metabolic Readiness. Journal of Immunology, 2015, 194, 2089-2098.	0.8	39
74	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research, 2015, 25, 208-224.	12.0	143
75	Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nature Medicine, 2015, 21, 998-1009.	30.7	736
76	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i>-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	9.4	696
77	The future of immune checkpoint therapy. Science, 2015, 348, 56-61.	12.6	3,735
78	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood, 2015, 125, 3335-3346.	1.4	55
79	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell, 2015, 161, 205-214.	28.9	1,872
80	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports, 2015, 13, 412-424.	6.4	387
81	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV ⁺ tumors when combined with an E6/E7 peptide vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5290-9.	7.1	79
82	Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunology Research, 2015, 3, 849-854.	3.4	32
83	Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980.	2.0	83
84	Checkpoints. Cell, 2015, 162, 1202-1205.	28.9	23
85	Immune Checkpoint Blockade in Cancer Therapy. JAMA - Journal of the American Medical Association, 2015, 314, 1113.	7.4	75
86	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515, 577-581.	27.8	1,705
87	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. Science Translational Medicine, 2014, 6, 226ra32.	12.4	590
88	Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility. Cancer Immunology Research, 2014, 2, 970-980.	3.4	68
89	Vaccination with tumor cells expressing IL-15 and IL-15RÎ± inhibits murine breast and prostate cancer. Gene Therapy, 2014, 21, 393-401.	4.5	30
90	Immune Modulation in Cancer with Antibodies. Annual Review of Medicine, 2014, 65, 185-202.	12.2	455

#	Article	IF	Citations
91	Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. Cancer Immunology Research, 2014, 2, 831-838.	3.4	270
92	Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. Journal of Experimental Medicine, 2014, 211, 715-725.	8.5	242
93	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell, 2014, 25, 719-734.	16.8	1,892
94	Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma. Annals of Surgical Oncology, 2013, 20, 3106-3111.	1.5	47
95	Immune Co-signaling to Treat Cancer. , 2013, , 211-280.		1
96	Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein. Clinical Cancer Research, 2013, 19, 6112-6125.	7.0	66
97	Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells. Science, 2013, 339, 1219-1224.	12.6	282
98	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences, 2013, 1291, 1-13.	3.8	270
99	Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy. Cancer Immunology Research, 2013, 1, 229-234.	3.4	178
100	Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. Journal of Experimental Medicine, 2013, 210, 743-755.	8.5	157
101	Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. Cancer Immunology Research, 2013, 1, 235-244.	3.4	109
102	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of antiâ€“CTLA-4 therapy against melanoma. Journal of Experimental Medicine, 2013, 210, 1695-1710.	8.5	1,203
103	Cutting Edge: Chronic Inflammatory Liver Disease in Mice Expressing a CD28-Specific Ligand. Journal of Immunology, 2013, 190, 526-530.	0.8	6
104	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. Journal of Experimental Medicine, 2013, 210, 1389-1402.	8.5	562
105	Response to Comment on â€œExpression of Helios in Peripherally Induced Foxp3+ Regulatory T Cellsâ€. Journal of Immunology, 2012, 189, 500.2-501.	0.8	3
106	Augmented IL-15RÎ± Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice. Journal of Immunology, 2012, 188, 6156-6164.	0.8	46
107	Cutting Edge: CTLA-4 on Effector T Cells Inhibits In <i>Trans</i>. Journal of Immunology, 2012, 189, 1123-1127.	0.8	94
108	B7x in the Periphery Abrogates Pancreas-Specific Damage Mediated by Self-reactive CD8 T Cells. Journal of Immunology, 2012, 189, 4165-4174.	0.8	29

#	ARTICLE	IF	CITATIONS
109	Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells. Journal of Immunology, 2012, 188, 976-980.	0.8	268
110	Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Antiâ€"CTLA-4 Therapy. Cancer Research, 2012, 72, 430-439.	0.9	248
111	Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6187-6192.	7.1	97
112	Lloyd J. Old (1933â€"2011). Science, 2012, 335, 49-49.	12.6	0
113	CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. OncoImmunology, 2012, 1, 544-546.	4.6	32
114	Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF-Î°B Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model. Neurotherapeutics, 2012, 9, 827-843.	4.4	33
115	Response to â€œIpilimumab (Yervoy) and the TGN1412 catastropheâ€• Immunobiology, 2012, 217, 590-592.	1.9	10
116	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	4.4	676
117	Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 2012, 366, 925-931.	27.0	1,836
118	Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 881-886.	7.1	84
119	Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. PLoS ONE, 2012, 7, e35222.	2.5	5
120	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature, 2012, 482, 400-404.	27.8	1,075
121	Integrated NY-ESO-1 antibody and CD8⁺T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16723-16728.	7.1	310
122	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
123	Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine, 2011, 17, 1094-1100.	30.7	476
124	Nobels: Toll pioneers deserve recognition. Nature, 2011, 479, 178-178.	27.8	4
125	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological Reviews, 2011, 241, 104-118.	6.0	229
126	Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature Reviews Cancer, 2011, 11, 805-812.	28.4	554

#	Article	IF	Citations
127	CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases. Cancer Immunology, Immunotherapy, 2011, 60, 1137-1146.	4.2	82
128	T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-Î²1 Cytokine. Immunity, 2011, 35, 123-134.	14.3	109
129	Strength of TCRâ€"Peptide/MHC Interactions and In Vivo T Cell Responses. Journal of Immunology, 2011, 186, 5039-5045.	0.8	182
130	Tissue-specific expression of B7x protects from CD4 T cellâ€"mediated autoimmunity. Journal of Experimental Medicine, 2011, 208, 1683-1694.	8.5	54
131	Single dose of antiâ€"CTLA-4 enhances CD8 ⁺ T-cell memory formation, function, and maintenance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 266-271.	7.1	151
132	Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production. PLoS ONE, 2011, 6, e19499.	2.5	189
133	Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Current Opinion in Immunology, 2010, 22, 326-332.	5.5	195
134	Antiâ€"CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy. Seminars in Oncology, 2010, 37, 473-484.	2.2	208
135	Singleâ€institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer, 2010, 116, 1767-1775.	4.1	405
136	Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals. Clinical Cancer Research, 2010, 16, 2781-2791.	7.0	118
137	TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. Journal of Experimental Medicine, 2010, 207, 1701-1711.	8.5	244
138	Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Clinical Cancer Research, 2010, 16, 2861-2871.	7.0	404
139	Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. Journal of Experimental Medicine, 2010, 207, 637-650.	8.5	715
140	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4275-4280.	7.1	1,602
141	Attenuated T Cell Responses to a High-Potency Ligand In Vivo. PLoS Biology, 2010, 8, e1000481.	5.6	99
142	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern Pathology, 2010, 23, 1104-1112.	5.5	204
143	Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors. Cancer Research, 2009, 69, 7747-7755.	0.9	120
144	Inhibitors of B7â€"CD28 costimulation in urologic malignancies. Immunotherapy, 2009, 1, 129-139.	2.0	10

#	Article	IF	Citations
145	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of antiâ€“CTLA-4 antibodies. Journal of Experimental Medicine, 2009, 206, 1717-1725.	8.5	785
146	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clinical and Experimental Immunology, 2009, 157, 9-19.	2.6	126
147	Negative regulators of Tâ€‰cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunological Reviews, 2009, 229, 67-87.	6.0	150
148	The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research. Clinical Cancer Research, 2009, 15, 5323-5337.	7.0	1,177
149	Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy, 2009, 11, 912-922.	0.7	35
150	Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunology, Immunotherapy, 2008, 57, 1263-1270.	4.2	54
151	Cell intrinsic mechanisms of Tâ€‰cell inhibition and application to cancer therapy. Immunological Reviews, 2008, 224, 141-165.	6.0	207
152	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20410-20415.	7.1	322
153	SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3509-3514.	7.1	46
154	Epitope Landscape in Breast and Colorectal Cancer. Cancer Research, 2008, 68, 889-892.	0.9	373
155	Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 ⁺ T Lymphocytes. Science, 2008, 319, 215-220.	12.6	103
156	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3005-3010.	7.1	604
157	Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. Journal of Experimental Medicine, 2008, 205, 2125-2138.	8.5	185
158	Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage. Cancer Research, 2008, 68, 6054-6058.	0.9	71
159	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood, 2008, 112, 1175-1183.	1.4	217
160	Alternative Activation Is an Innate Response to Injury That Requires CD4+ T Cells to be Sustained during Chronic Infection. Journal of Immunology, 2007, 179, 3926-3936.	0.8	230
161	A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2007, 13, 1810-1815.	7.0	385
162	Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17765-17770.	7.1	97

#	Article	IF	Citations
163	Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function. Clinical Cancer Research, 2007, 13, 2158-2167.	7.0	293
164	B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19458-19463.	7.1	336
165	Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of Î² cells. Blood, 2007, 110, 954-961.	1.4	25
166	T Cell Immunoglobulin Mucin-3 Crystal Structure Reveals a Galectin-9-Independent Ligand-Binding Surface. Immunity, 2007, 26, 311-321.	14.3	183
167	The B7 Family and Cancer Therapy: Costimulation and Coinhibition. Clinical Cancer Research, 2007, 13, 5271-5279.	7.0	308
168	Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative. Cancer Cell, 2007, 12, 192-199.	16.8	65
169	Immunotherapeutic Strategies for High-Risk Bladder Cancer. Seminars in Oncology, 2007, 34, 165-172.	2.2	29
170	Checkpoint Blockade and Combinatorial Immunotherapies. , 2007, , 363-390.		0
171	Checkpoint Blockade in Cancer Immunotherapy. Advances in Immunology, 2006, 90, 297-339.	2.2	498
172	A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics, 2006, 88, 841-845.	2.9	12
173	Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 442-447.	1.6	40
174	Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 2006, 439, 682-687.	27.8	3,471
175	Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Current Opinion in Immunology, 2006, 18, 206-213.	5.5	426
176	CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism. Journal of Immunology, 2006, 177, 1052-1061.	0.8	112
177	CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. Journal of Clinical Investigation, 2006, 116, 1935-1945.	8.2	605
178	To be or not to be B7. Journal of Clinical Investigation, 2006, 116, 2590-2593.	8.2	20
179	Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. British Journal of Haematology, 2005, 130, 809-824.	2.5	46
180	Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9872-9877.	7.1	21

#	Article	IF	Citations
181	Regulated Costimulation in the Thymus Is Critical for T Cell Development: Dysregulated CD28 Costimulation Can Bypass the Pre-TCR Checkpoint. Journal of Immunology, 2005, 175, 4199-4207.	0.8	50
182	Engagement of NKG2D by Cognate Ligand or Antibody Alone Is Insufficient to Mediate Costimulation of Human and Mouse CD8+ T Cells. Journal of Immunology, 2005, 174, 1922-1931.	0.8	96
183	Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clinical Cancer Research, 2005, 11, 728-34.	7.0	662
184	B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions. Journal of Immunology, 2004, 172, 34-39.	0.8	118
185	MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). International Immunology, 2004, 16, 895-904.	4.0	9
186	Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation. Journal of Immunology, 2004, 173, 6098-6108.	0.8	234
187	Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Research, 2004, 6, 208.	2.0	23
188	CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine, 2004, 22, 1700-1708.	3.8	116
189	B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse. Immunity, 2004, 21, 401-413.	14.3	390
190	CD28 disruption exacerbates inflammation in Tgf-Î²1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-Î²1. Blood, 2004, 103, 4594-4601.	1.4	75
191	BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nature Immunology, 2003, 4, 670-679.	14.5	768
192	Prostate Cancer. BioDrugs, 2003, 17, 131-138.	4.6	11
193	Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4712-4717.	7.1	940
194	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5336-5341.	7.1	536
195	B7x: A widely expressed B7 family member that inhibits T cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10388-10392.	7.1	362
196	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8372-8377.	7.1	1,482
197	Protein Localization in Negative Signaling. , 2003, , 355-359.		0
198	Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3013-3017.	7.1	69

#	Article	IF	Citations
199	Cutting Edge: A Crucial Role for B7-CD28 in Transmitting T Help from APC to CTL. Journal of Immunology, 2002, 169, 4094-4097.	0.8	54
200	The lymphoproliferative defect in CTLA-4â€“deficient mice is ameliorated by an inhibitory NK cell receptor. Blood, 2002, 99, 4509-4516.	1.4	10
201	Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength. Immunity, 2002, 16, 23-35.	14.3	452
202	CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunology, 2002, 3, 611-618.	14.5	843
203	CTLA-4-MEDIATEDINHIBITION INREGULATION OFT CELLRESPONSES: Mechanisms and Manipulation in Tumor Immunotherapy. Annual Review of Immunology, 2001, 19, 565-594.	21.8	905
204	Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine. Journal of Experimental Medicine, 2001, 194, 481-490.	8.5	307
205	ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature, 2001, 409, 97-101.	27.8	840
206	Synergism of Cytotoxic T Lymphocyteâ€“Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses. Journal of Experimental Medicine, 2001, 194, 823-832.	8.5	959
207	Lack of a role for transforming growth factor-Â in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 2587-2592.	7.1	50
208	Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 12711-12716.	7.1	64
209	Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 12204-12209.	7.1	95
210	The Role of B7 Costimulation in CD4/CD8 T Cell Homeostasis. Journal of Immunology, 2000, 164, 3543-3553.	0.8	56
211	Cytotoxic T Lymphocyte Antigen 4 (CD152) Regulates Self-Reactive T cells in BALB/c but not in the Autoimmune NOD Mouse. Journal of Autoimmunity, 2000, 14, 123-131.	6.5	14
212	In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 11476-11481.	7.1	155
213	Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 15074-15079.	7.1	214
214	Combination Immunotherapy of B16 Melanoma Using Antiâ€“Cytotoxic T Lymphocyteâ€“Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation. Journal of Experimental Medicine, 1999, 190, 355-366.	8.5	951
215	Costimulatory regulation of T cell function. Current Opinion in Cell Biology, 1999, 11, 203-210.	5.4	359
216	Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4+ T cell responses. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8603-8608.	7.1	119

#	Article	IF	Citations
217	Cytotoxic T Lymphocyteâ€"associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes. Journal of Experimental Medicine, 1998, 187, 427-432.	8.5	277
218	Repression of B7.2 on Self-reactive B Cells Is Essential to Prevent Proliferation and Allow Fas-mediated Deletion by CD4+ T Cells. Journal of Experimental Medicine, 1998, 188, 651-659.	8.5	89
219	CTLA-4 blockade synergizes with tumor-derived granulocyteâ€" macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10067-10071.	7.1	356
220	Itk Negatively Regulates Induction of â€‰T Cell Proliferation by CD28 Costimulation. Journal of Experimental Medicine, 1997, 186, 221-228.	8.5	48
221	Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9273-9278.	7.1	175
222	Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 8099-8103.	7.1	364
223	T Cellâ€"Mediated Elimination of B7.2 Transgenic B Cells. Immunity, 1997, 6, 327-339.	14.3	43
224	The Emerging Role of CTLA-4 as an Immune Attenuator. Immunity, 1997, 7, 445-450.	14.3	582
225	Lymphoproliferation in CTLA-4â€"Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells. Immunity, 1997, 7, 885-895.	14.3	384
226	Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. Journal of Neuroimmunology, 1997, 73, 57-62.	2.3	99
227	Thymocyte development is normal in CTLA-4-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9296-9301.	7.1	137
228	Lymphocyte activation and effector functions How signals are integrated in the immune system. Current Opinion in Immunology, 1997, 9, 293-295.	5.5	2
229	Co-stimulation in T cell responses. Current Opinion in Immunology, 1997, 9, 396-404.	5.5	401
230	Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science, 1996, 271, 1734-1736.	12.6	3,231
231	The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction. European Journal of Immunology, 1996, 26, 3224-3229.	2.9	24
232	CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.. Journal of Experimental Medicine, 1996, 183, 2533-2540.	8.5	837
233	Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. International Immunology, 1996, 8, 519-523.	4.0	128
234	Manipulation of costimulatory signals to enhance antitumor T-cell responses. Current Opinion in Immunology, 1995, 7, 682-686.	5.5	158

#	Article	IF	Citations
235	CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.. Journal of Experimental Medicine, 1995, 182, 459-465.	8.5	1,922
236	The role of short homology repeats and TdT in generation of the invariant Î³Î´ antigen receptor repertoire in the fetal thymus. Immunity, 1995, 3, 439-447.	14.3	61
237	The Yin and Yang of T Cell Costimulation. Science, 1995, 270, 932-932.	12.6	172
238	CD28-B7 interactions in T-cell activation. Current Opinion in Immunology, 1994, 6, 414-419.	5.5	298
239	Î³Î´ T-cell development. Current Opinion in Immunology, 1993, 5, 241-246.	5.5	55
240	CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.. Journal of Experimental Medicine, 1993, 177, 1791-1796.	8.5	265
241	Co-stimulation via CD28 induces activation of a refractory subset of MRL-Ipr/Ipr T lymphocytes. International Immunology, 1993, 5, 1451-1460.	4.0	15
242	T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. International Immunology, 1993, 5, 145-153.	4.0	59
243	Activation and differentiation requirements of primary T cells in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8987-8991.	7.1	95
244	Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage.. Journal of Experimental Medicine, 1993, 177, 1061-1070.	8.5	21
245	Intrathymic differentiation of V gamma 3 T cells.. Journal of Experimental Medicine, 1993, 178, 309-315.	8.5	45
246	CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature, 1992, 356, 607-609.	27.8	1,516
247	Expression of a fetal Î³Î´ T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. International Immunology, 1991, 3, 385-393.	4.0	20
248	Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. Nature, 1990, 344, 68-70.	27.8	299
249	Nucleotide and deduced amino acid sequence of a murine cDNA clone encoding one member of the hsp65 multigene family. Nucleic Acids Research, 1990, 18, 7153-7153.	14.5	6
250	Diminished Expression of the T Cell Receptor on the Expanded Lymphocyte Population in Mrl/Mp-1pr/1prMice. Autoimmunity, 1989, 2, 97-111.	2.6	9
251	Antibodies against the T cell receptor/CD3 complex interfere with distinct intra-thymic cell-cell interactionsin vivo: correlation with arrest of T cell differentiation. European Journal of Immunology, 1989, 19, 857-863.	2.9	29
252	Characterization ofenv gene recombination in X-ray-induced thymomas of C57BL76 mice. Molecular Carcinogenesis, 1989, 2, 126-130.	2.7	6

#	Article	IF	Citations
253	Î³Î´ Antigen receptors of Thy-1 + dendritic epidermal cells: Implications for thymic differentiation. Immunologic Research, 1988, 7, 292-302.	2.9	7
254	Limited diversity of Î³Î´ antigen receptor genes of thy-1+ dendritic epidermal cells. Cell, 1988, 55, 837-847.	28.9	523
255	The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer.. Journal of Experimental Medicine, 1987, 165, 1076-1094.	8.5	168
256	A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. Cell, 1987, 49, 143-151.	28.9	66
257	Structure, Function, and Serology of the T-Cell Antigen Receptor Complex. Annual Review of Immunology, 1987, 5, 503-540.	21.8	240
258	The gamma T-cell antigen receptor. Journal of Clinical Immunology, 1987, 7, 429-440.	3.8	23
259	The T-cell antigen receptor gamma gene: rearrangement and cell lineages. Trends in Immunology, 1987, 8, 293-296.	7.5	60
260	The congenic mutant B6.C-H-2bmâˆ'1 (H-2bmâˆ'1) serological response to the T-cell receptor on EL4. Cellular Immunology, 1986, 101, 586-592.	3.0	0
261	Identification of antigen receptor-associated structures on murine T cells. Nature, 1985, 314, 107-109.	27.8	85
262	Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. Experimental Cell Research, 1985, 158, 509-518.	2.6	55
263	Structural Differences in Envelope Glycoproteins Associated with Rat Leukaemia Virus Produced by Novikoff Hepatocellular Carcinoma and Spontaneously Transformed Wistar Rat Embryo Cells. Journal of General Virology, 1984, 65, 743-760.	2.9	0
264	The Murine T Cell Antigen Receptor and Associated Structures. Immunological Reviews, 1984, 81, 145-160.	6.0	26
265	Cell surface expression by adult rat hepatocytes of a non-collagen glycoprotein present in rat liver biomatrix. Experimental Cell Research, 1984, 152, 402-414.	2.6	25
266	Biosynthesis and processing of murine T-cell antigen receptor. Cell, 1984, 38, 659-665.	28.9	29
267	[55] HLA antigens in serum. Methods in Enzymology, 1984, 108, 614-624.	1.0	36
268	Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma. Immunogenetics, 1983, 17, 655-659.	2.4	2
269	The mouse T cell receptor: Structural heterogeneity of molecules of normal T cells defined by Xenoantiserum. Cell, 1983, 34, 739-746.	28.9	220
270	Chemical and immunological characterization of developmentally expressed chicken erythroid surface membrane antigens. Developmental Biology, 1982, 91, 389-396.	2.0	20

#	Article	IF	Citations
271	Hâ€“2 Antigens on a murine lymphoma are associated with additional proteins. Nature, 1978, 271, 165-167.	27.8	30
272	Murine Ia and human DR antigens: homology of amino-terminal sequences.. Proceedings of the National Academy of Sciences of the United States of America, 1978, 75, 3953-3956.	7.1	119
273	Training Procedures and Task Difficulty in Brightness and Position Discriminations by Rats. Psychological Reports, 1972, 31, 71-76.	1.7	2
274	Insolubilization of L-asparaginase by covalent attachment to nylon tubing. Biochemical and Biophysical Research Communications, 1972, 47, 66-73.	2.1	58
275	The substrate specificity of L-asparaginase fromAlcaligenes eutrophus. FEBS Letters, 1971, 14, 107-108.	2.8	14